RENEO PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.66 USD | -3.49% |
|
-.--% | +3.75% |
| May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
| May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 208.8 | 57.15 | 53.3 | 55.48 | - |
| Enterprise Value (EV) 1 | 61.15 | 57.15 | 53.3 | 55.48 | 55.48 |
| P/E ratio | -3.9 x | -1.1 x | -0.63 x | -2.55 x | -2.41 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -5,618,689 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,424 | 24,530 | 33,312 | 33,421 | - |
| Reference price 2 | 8.550 | 2.330 | 1.600 | 1.660 | 1.660 |
| Announcement Date | 3/23/22 | 3/27/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -39.82 | -53.85 | -83.05 | -25.75 | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -39.77 | -51.96 | -77.39 | -21.99 | - |
| Net income 1 | -19.46 | -39.77 | -51.96 | -77.39 | -21.99 | -23.6 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -9.576 | -2.190 | -2.120 | -2.520 | -0.6500 | -0.6900 |
| Free Cash Flow | - | -37.17 | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/23/22 | 3/27/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -10.62 | -13.02 | -12.43 | -13.84 | -14.56 | -16.12 | -21.04 | -20.89 | -25.01 | -9.564 | -4.25 | -3.25 | -3.25 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -10.61 | -13.04 | -12.31 | -13.01 | -13.6 | -15.11 | -19.53 | -19.2 | -23.55 | -8.426 | -3.329 | -2.35 | -2.359 |
| Net income 1 | -10.61 | -13.04 | -12.31 | -13.01 | -13.6 | -15.11 | -19.53 | -19.2 | -23.55 | -8.426 | -3.329 | -2.35 | -2.359 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3700 | -0.5300 | -0.5000 | -0.5300 | -0.5500 | -0.6000 | -0.6500 | -0.5700 | -0.7100 | -0.2500 | -0.1000 | -0.0700 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/27/23 | 5/11/23 | 8/10/23 | 11/13/23 | 3/28/24 | 5/7/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 148 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -37.2 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.2 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/23/22 | 3/27/23 | 3/28/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.66
USD
Average target price
1.833
USD
Spread / Average Target
+10.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.75% | 55.48M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- RPHM Stock
- Financials Reneo Pharmaceuticals, Inc.
